keyword
MENU ▼
Read by QxMD icon Read
search

Vegf eye

keyword
https://www.readbyqxmd.com/read/29225458/antiangiogenic-effect-of-dasatinib-in-murine-models-of-oxygen-induced-retinopathy-and-laser-induced-choroidal-neovascularization
#1
Songyi Seo, Wonhee Suh
Purpose: Vascular endothelial growth factor (VEGF) is a principal mediator of pathological ocular neovascularization, which is the leading cause of blindness in various ocular diseases. As Src, a non-receptor tyrosine kinase, has been implicated as one of the major signaling molecules in VEGF-mediated neovascularization, the present study aimed to investigate whether dasatinib, a potent Src kinase inhibitor, could suppress pathological ocular neovascularization in murine models of oxygen-induced retinopathy (OIR) and choroidal neovascularization (CNV)...
2017: Molecular Vision
https://www.readbyqxmd.com/read/29217515/choroidal-neovascular-membrane-in-paediatric-patients-clinical-characteristics-and-outcomes
#2
Tapas Ranjan Padhi, Bradley J Anderson, Ashkan M Abbey, Yoshihiro Yonekawa, Maxwell Stem, Danish Alam, Rohit Ramesh Modi, Laxmi Prabhavathi Savla, Michael T Trese, Antonio Capone, Kimberly A Drenser, Cagri G Besirli
PURPOSE: To analyse the clinical characteristics and treatment outcomes of choroidal neovascular membranes (CNVM) in paediatric subjects at three paediatric retina referral centres. METHODS: Medical charts of patients aged 18 years or less with a diagnosis of CNVM were retrospectively reviewed. The demographic profile, laterality, presenting complaint, corrected vision, underlying pathology, fundus, fundus fluorescein angiogram and optical coherence tomogram (OCT) were analysed...
December 7, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/29207076/antiangiogenic-effects-of-catalpol-on-rat-corneal%C3%A2-neovascularization
#3
Yun Han, Mei Shen, Li-Yuan Tang, Gang Tan, Qi-Chen Yang, Lei Ye, Lin-Hong Ye, Nan Jiang, Gui-Ping Gao, Yi Shao
To investigate the effects of catalpol on corneal neovascularization (CNV) and associated inflammation, eye drops (5 mM catalpol or PBS) were administered four times daily to alkali‑burn rat models of CNV and inflammation. Clinical evaluations of CNV and the degree of inflammation were performed on days 0, 4, 7, 10 and 14 under slit lamp microscopy. Eyes were collected on day 14 and prepared for hematoxylin and eosin, and immunofluorescence staining; corneal cell apoptosis was investigated via terminal deoxynucleotidyl transferase‑mediated nick end labeling (TUNEL) staining...
November 20, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29205985/current-care-guideline-age-related-macular-degeneration-amd
#4
(no author information available yet)
Age-related macular degeneration (AMD) is the main cause of visual impairment in developed countries. Several improvements in the visualization of posterior segment of the eye together with the introduction of intravitreal anti-VEGF treatment have revolutionized the prognosis of the wet form of AMD (wAMD). Increasing incidence of wAMD together with the limited resources of the healthcare systems pose challenges for the provision and development of care. In context of these current aspects, we aim to set evidence-based guidelines for diagnosis, treatment and follow-up of patients with wAMD...
2017: Duodecim; Lääketieteellinen Aikakauskirja
https://www.readbyqxmd.com/read/29204996/the-vegf-treatment-of-amd-switch-study-the-vtas-study
#5
Beverley Curry, Guy Bylsma, Alex W Hewitt, Nitin Verma
PURPOSE: To evaluate the effect of aflibercept on anatomic and visual outcomes in patients with choroidal neovascularization (CNV) previously treated with intravitreal ranibizumab with persistent fluid on optical coherence tomography (OCT). DESIGN: Prospective, open-label study. METHODS: Eighteen patients (19 eyes) with CNV being treated with monthly ranibizumab, with persistent fluid on OCT, were switched to intravitreal aflibercept injections at intervals of up to 8 weeks...
November 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/29204069/the-role-of-focal-laser-in-the-anti-vascular-endothelial-growth-factor-era
#6
REVIEW
Jason N Crosson, Lauren Mason, John O Mason
Introduction: To review important studies examining focal laser for diabetic macular edema (DME), to examine real-world data regarding actual treatments patients are receiving, to present long-term visual outcomes in real-world practice, and to suggest an evidence-based approach for the use of focal laser. Methods: This study is a review of landmark studies evaluating focal laser and pharmacologic therapy for DME. In addition, the authors include a retrospective review of 102 consecutive eyes of 53 patients in our practice setting in rural Alabama...
2017: Ophthalmology and Eye Diseases
https://www.readbyqxmd.com/read/29196768/macular-atrophy-development-and-subretinal-drusenoid-deposits-in-anti-vascular-endothelial-growth-factor-treated-age-related-macular-degeneration
#7
Anna V Zarubina, Orly Gal-Or, Carrie E Huisingh, Cynthia Owsley, K Bailey Freund
Purpose: To explore the association between presence of subretinal drusenoid deposits (SDD) at baseline in eyes with neovascular age-related macular degeneration (nAMD) with the development of macular atrophy (MA) during anti-vascular endothelial growth factor (VEGF) therapy. Methods: There were 74 eyes without pre-existing MA receiving anti-VEGF therapy for nAMD for 2 years or longer analyzed. At least two image modalities that included spectral-domain optical coherence tomography, near-infrared reflectance, fluorescein angiography, and color fundus photos were used to assess for SDD presence, phenotype (dot and ribbon), and location, neovascularization type, and MA...
December 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29190236/apoptosis-and-angiofibrosis-in-diabetic-tractional-membranes-after-vascular-endothelial-growth-factor-inhibition-results-of-a-prospective-trial-report-no-2
#8
Chunhua Jiao, Dean Eliott, Christine Spee, Shikun He, Kai Wang, Robert F Mullins, David R Hinton, Elliott H Sohn
PURPOSE: We sought to characterize the angiofibrotic and apoptotic effects of vascular endothelial growth factor (VEGF)-inhibition on fibrovascular epiretinal membranes in eyes with traction retinal detachment because of proliferative diabetic retinopathy. METHODS: Membranes were excised from 20 eyes of 19 patients (10 randomized to intravitreal bevacizumab, 10 controls) at vitrectomy. Membranes were stained with antibodies targeting connective tissue growth factor (CTGF) or VEGF and colabeled with antibodies directed against endothelial cells (CD31), myofibroblasts, or retinal pigment epithelium markers...
November 22, 2017: Retina
https://www.readbyqxmd.com/read/29185408/high-altitude-retinopathy-presenting-as-central-retinal-vein-occlusion-in-a-soldier
#9
Waseem Raja, Ahsan Mukhtar
A 33-year soldier, deployed at an altitude of 3,350 meters for two years, developed unilateral Central Retinal Vein Occlusion (CRVO) in the left eye. He had no risk factor for thrombosis and all thrombophilia screenings were negative. The patient was managed with intravitreal injections of anti-VEGF (Bevacizumab) every four weeks. He showed gradual improvement in the visual acuity over the next 3 months. Best corrected visual acuity (BCVA) after three months was 6/7.5; whereas, initially it was limited to hand movements only...
December 2017: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/29184088/comparison-of-two-year-outcomes-after-photodynamic-therapy-with-ranibizumab-or-aflibercept-for-polypoidal-choroidal-vasculopathy
#10
Wataru Kikushima, Yoichi Sakurada, Atsushi Sugiyama, Seigo Yoneyama, Naohiko Tanabe, Mio Matsubara, Fumihiko Mabuchi, Hiroyuki Iijima
Photodynamic therapy (PDT) combined with intravitreal anti-vascular endothelial growth factor (VEGF) agents is currently the first-line treatment for polypoidal choroidal vasculopathy (PCV), along with anti-VEGF monotherapy. In this study, 100 eyes with treatment-naïve PCV were initially treated with PDT combined with intravitreal ranibizumab (IVR; n = 57) or aflibercept (IVA; n = 43). We compared two-year outcomes between these two groups and investigated factors associated with visual improvement and retreatment over 24 months...
November 28, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29180844/vitreoretinal-interface-abnormalities-in-diabetic-macular-edema-and-effectiveness-of-anti-vegf-therapy-an-optical-coherence-tomography-study
#11
Alexei N Kulikov, Sergei V Sosnovskii, Roman D Berezin, Dmitrii S Maltsev, Dzhambulat H Oskanov, Nikolai A Gribanov
Purpose: To study vitreoretinal interface (VRI) abnormalities in diabetic macular edema (DME) and the influence of these on the effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) therapy. Methods: VRI status and central retinal thickness (CRT) were evaluated using line and 3D-reference scans obtained using spectral domain-optical coherence tomography RTVue-100 before and 1 month after intravitreal anti-VEGF injection (IVI). VRI status was categorized into five subgroups: normal VRI, retinal surface wrinkling associated with the eccentric epiretinal membrane (ERM), ERM involving the macular center, vitreomacular adhesion (VMA), and vitreomacular traction (VMT)...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/29179221/-vitreomacular-traction-following-anti-vegf-therapy-two-cases
#12
Sophie Helene Wallraf, Kristina Markova, Christos Haritoglou
Vitreomacular traction syndrome (VMTS) is defined as an incomplete or anomalous posterior vitreous detachment resulting in tractional forces at the macular region. In the context of anti-VEGF therapy, the formation of vitreoretinal traction has mainly been reported as a potential complication of VEGF inhibition in ischemic proliferative retinal disease, such as proliferative diabetic retinopathy. In this report, we present two patients who developed VMTS during anti-VEGF therapy for exudative age-related macular degeneration and diabetic macular edema...
November 27, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/29166140/comparison-of-short-term-choroidal-thickness-and-retinal-morphological-changes-after-intravitreal-anti-vegf-therapy-with-ranibizumab-or-aflibercept-in-treatment-naive-eyes
#13
Magda Gharbiya, Rosalia Giustolisi, Jessica Marchiori, Alice Bruscolini, Fabiana Mallone, Valeria Fameli, Marcella Nebbioso, Solmaz Abdolrahimzadeh
PURPOSE: To evaluate choroidal thickness (CT) and retinal morphological changes in eyes with neovascular age-related macular degeneration (nAMD) following ranibizumab or aflibercept intravitreal treatment. MATERIALS AND METHODS: This was a prospective, observational, comparative study where 76 eyes of 76 consecutive patients with treatment-naive nAMD were consecutively enrolled and randomized to ranibizumab 0.5 mg or aflibercept 2 mg injections. Spectral-domain optical coherence tomography images of the choroid were obtained by enhanced depth imaging modality...
November 22, 2017: Current Eye Research
https://www.readbyqxmd.com/read/29165417/-pterygium-etiology-pathogenesis-treatment
#14
S A Malozhen, S V Trufanov, D A Krakhmaleva
Pterygium is a degenerative condition characterized by fibrovascular outgrowth of conjunctiva over the cornea. Many theories exist that try to explain its pathogenesis. The current belief is that this disease is multifactorial with ultraviolet radiation being the most important trigger. Attention is also paid to such factors as tear film changes, cytokines and growth factors disbalance, immunologic disturbances, genetic mutations, and viral infections. Modern classifications consider the rate of fibrovascular growth, its progressive potential, and histological features...
2017: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/29158262/the-epac-rap1-pathway-prevents-and-reverses-cytokine-induced-retinal-vascular-permeability
#15
Carla J Ramos, Chengmao Lin, Xuwen Liu, David A Antonetti
Increased retinal vascular permeability contributes to macular edema, a leading cause of vision loss in eye pathologies such as diabetic retinopathy, age-related macular degeneration, and central retinal vein occlusions. Pathological changes in vascular permeability are driven by growth factors such as VEGF and by pro-inflammatory cytokines such as TNF-α. Identifying the pro-barrier mechanisms that block vascular permeability and restore the blood-retinal barrier (BRB) may lead to new therapies. The cAMP-dependent guanine nucleotide exchange factor EPAC promotes exchange of GTP in the small GTPase Rap1...
November 20, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/29148027/sequential-tissue-plasminogen-activator-pneumatic-displacement-and-anti-vegf-treatment-for-submacular-hemorrhage
#16
Handan Bardak, Yavuz Bardak, Yeşim Erçalık, Burak Erdem, Gökhan Arslan, Semrin Timlioglu
PURPOSE: To report the results of our sequential intravitreal (IV) tissue plasminogen activator (tPA), pneumatic displacement (PD), and IV anti-vascular endothelial growth factor (VEGF) treatment in patients with neovascular age-related macular degeneration (nAMD)-related submacular hemorrhage (SMH). METHODS: A total of 16 eyes of 16 patients with SMH of less than 15 days duration were included in this retrospective pilot study. The tPA was applied on the day of diagnosis, and PD was performed the following day...
November 4, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/29137019/optical-coherence-tomography-angiography-in-patients-with-diabetic-retinopathy-treated-with-anti-vegf-intravitreal-injections-case-report
#17
Katarzyna Michalska-Małecka, Anna Heinke Knudsen
PURPOSE: To present optical coherence tomography angiography (OCTA) features in patients with diabetic retinopathy (DR) at the baseline and in response to treatment with anti-VEGF intravitreal injections. To investigate the role of OCTA in management of patients with DR. METHODS: Retrospective case series showing primary outcomes of 3 patients with DR and diabetic macular edema. Patients were injected intravitreally a loading phase of 3 monthly 2.0 mg aflibercept, followed by 2 injections bimonthly (5 injections in total)...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29134820/pharmacokinetics-of-intravitreal-anti-vegf-drugs-in-vitrectomized-versus-non-vitrectomized-eyes
#18
Magdalena Edington, Julie Connolly, Ngaihang Victor Chong
Introduction The review aims to discuss effects of vitrectomy on pharmacokinetics of anti-vascular endothelial growth factor (anti-VEGF) agents, and attempt to provide treatment guidance. Areas Covered An Embase search was conducted using the terms 'anti-VEGF', 'pegaptanib', 'ranibizumab', 'bevacizumab', 'aflibercept', 'pharmacokinetics', 'half-life', 'clearance', 'metabolism', 'vitrectomy', 'vitrectomized'. Published data regarding the pharmacokinetic properties of the above drugs and the effect of vitrectomy in animal and human eyes was reviewed...
November 14, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29133637/the-inhibitory-effect-of-different-concentrations-of-kh902-eye-drops-on-corneal-neovascularization-induced-by-alkali-burn
#19
Yan Wu, Chunyan Xue, Yan Lu, Zhenping Huang
PURPOSE: The aim of this study was to evaluate the inhibitory effect of different concentrations of KH902 eye drops on rabbit corneal neovascularization (CNV) induced by alkali burn. METHODS: Forty-eight adult rabbits were randomized into four groups after alkali burning: Group A (2.5 mg/ml), Group B (5 mg/ml), and Group C (10 mg/ml) by different concentrations of KH902 eye drops and Group D by saline solution as control with three times a day for 2 weeks. At days 7, 14, and 28, the anterior segment photographs, confocal microscopy, and histopathology were performed to evaluate corneal opacity, neovascularization, inflammatory cell density, vessel size, and edema...
November 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/29131696/risk-factors-for-discontinuation-of-treatment-for-neovascular-age-related-macular-degeneration
#20
Inger Westborg, Aldana Rosso
PURPOSE: To investigate risk factors for treatment discontinuation for neovascular age-related macular degeneration (nAMD). METHODS: Data from the Swedish Macula Register and the Skåne Healthcare Register are reported on the treatment received by 932 nAMD patients diagnosed 2013-2015. Treatment discontinuation is defined as having a termination visit or lacking a control or treatment visit during the period of 10-14 months after the diagnostic visit. The risk of treatment discontinuation during the first year is estimated using a Poisson model and a classification tree...
November 13, 2017: Ophthalmic Epidemiology
keyword
keyword
4979
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"